Posted by Michael Wonder on 22 Jan 2022
FDA takes actions to expand use of treatment for outpatients with mild to moderate COVID-19
21 January 2022 - Today, the U.S. FDA took two actions to expand the use of the antiviral drug Veklury (remdesivir) to certain non-hospitalised adults and paediatric patients for the treatment of mild-to-moderate COVID-19 disease.
This provides another treatment option to reduce the risk of hospitalisation in high-risk patients.
Previously, the use of Veklury was limited to patients requiring hospitalisation.
